David Snipelisky
Overview
Explore the profile of David Snipelisky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yan C, Snipelisky D, Velez M, Baran D, Estep J, Bauerlein E, et al.
Am Heart J Plus
. 2024 Sep;
45:100438.
PMID: 39220718
The objective of our study was to evaluate the real-world effects of an aggressive, personalized protocol for guideline-directed medical therapy (GDMT) titration in patients with heart failure (HF) with reduced...
2.
Snipelisky D, Estep J
Heart Fail Clin
. 2024 Aug;
20(4):445-454.
PMID: 39216929
Cardiogenic shock is a multisystem pathology that carries a high mortality rate, and initial pharmacotherapies include the use of vasopressors and inotropes. These agents can increase myocardial oxygen consumption and...
3.
Alonso M, Neicheril R, Manla Y, McDonald M, Sanchez A, Lafave G, et al.
ESC Heart Fail
. 2024 Aug;
11(6):3649-3655.
PMID: 39180423
Aims: Transthyretin cardiac amyloidosis (ATTR-CA) is most often associated with heart failure with preserved ejection fraction (HFpEF). However, patients may present with impaired systolic function at the time of diagnosis,...
4.
McDonald M, Manla Y, Sonnino A, Alonso M, Neicheril R, Sanchez A, et al.
Clin Cardiol
. 2024 Jun;
47(6):e24298.
PMID: 38873847
Background: In patients with transthyretin cardiac amyloidosis (ATTR-CA), renal dysfunction is a poor prognostic indicator. Limited data are available on variables that portend worsening renal function (wRF) among ATTR-CA patients....
5.
Baran D, Snipelisky D
JACC Heart Fail
. 2024 Jun;
12(6):1071-1072.
PMID: 38839150
No abstract available.
6.
Neicheril R, Snipelisky D
Curr Opin Cardiol
. 2024 Jan;
39(2):104-109.
PMID: 38170194
Purpose Of Review: The role of inotropes has evolved with its use now expanding over multiple indications including cardiogenic shock, low cardiac output states, bridging therapy to transplant or mechanical...
7.
Snipelisky D, Estep J
Cardiol Clin
. 2023 Sep;
41(4):583-592.
PMID: 37743080
Cardiogenic shock is a multisystem pathology that carries a high mortality rate, and initial pharmacotherapies include the use of vasopressors and inotropes. These agents can increase myocardial oxygen consumption and...
8.
Watson K, Wolinsky D, Velez M, Snipelisky D
Cleve Clin J Med
. 2023 Feb;
90(2):95-101.
PMID: 36724919
No abstract available.
9.
Zahid S, Sanchez-Nadales A, Hashem A, Sarkar A, Sleiman J, Lewis A, et al.
Curr Probl Cardiol
. 2022 Nov;
48(2):101488.
PMID: 36351464
Left atrial appendage occlusion using the Watchman device has emerged as an alternative treatment strategy for preventing strokes in patients with atrial fibrillation. However, there is no data on its...
10.
Rohm C, Howard B, Lakhani B, Wilim M, Holden R, Snipelisky D
Tex Heart Inst J
. 2021 Jul;
48(3).
PMID: 34243189
Aortic insufficiency with recirculation can be difficult to diagnose echocardiographically in patients who have continuous-flow left ventricular assist devices. Transthoracic and transesophageal echocardiography can underestimate its severity; moreover, transesophageal echocardiography...